Rab Prinjha
Director/Board Member at Padlock Therapeutics, Inc.
Profile
Rab Prinjha is currently a Director at Padlock Therapeutics, Inc. He previously worked as the Head of Epigenetics Discovery Performance Unit at GSK Plc.
He obtained a doctorate degree from University College London.
Rab Prinjha active positions
| Companies | Position | Start |
|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Former positions of Rab Prinjha
| Companies | Position | End |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Training of Rab Prinjha
| University College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private companies | 1 |
|---|---|
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Rab Prinjha
